Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213237 | 0.88 | GPR52 (0.55) | GPR52KMT2AALDH1A1MEN1ANO1 | |
| SCHEMBL1862448 | 0.86 | GPR52 (0.51) | GPR52SYKMAPTKMT2ANPC1 | |
| SCHEMBL13505468 | 0.85 | GPR52 (0.69) | GPR52MAPTKMT2ANPC1ALDH1A1 | |
| SCHEMBL3220894 | 0.83 | GPR52 (0.75) | GPR52 | |
| SCHEMBL1851359 | 0.81 | GPR52 (0.51) | GPR52SYKMAPTKMT2ANPC1 | |
| SCHEMBL3201706 | 0.80 | GPR52 (0.62) | GPR52 | |
| SCHEMBL1851784 | 0.76 | GPR52 (0.56) | GPR52NR3C2 | |
| SCHEMBL1856053 | 0.75 | GPR52 (0.56) | GPR52SYKMAPTKMT2ANPC1 | |
| SCHEMBL3209948 | 0.74 | GPR52 (0.48) | GPR52SYKMAPTKMT2ANPC1 | |
| SCHEMBL1855671 | 0.74 | BRAF (0.51) | SYKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885SYK 1791/4885MAPT 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.